Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) is a common mutation in acute myeloid leukemia (AML), particularly with normal cytogenetics.
• FLT3 mutations (ITD and tyrosine kinase domain - TKD) are linked to poor prognosis, drug resistance, and increased relapse risk in AML.
• Several FLT3 inhibitors are under investigation, with midostaurin and gilteritinib FDA-approved for FLT3-mutated AML.

Purpose of the Study:

• To summarize the clinical trials evaluating gilteritinib for AML treatment.
• To highlight gilteritinib's efficacy in relapsed/refractory (R/R) FLT3-mutated AML based on the ADMIRAL study.
• To discuss the potential of gilteritinib as a new standard of care for R/R FLT3-mutated AML.

Main Methods:

• Review of clinical trial data for gilteritinib in AML.
• Analysis of the ADMIRAL study comparing gilteritinib to salvage chemotherapy in R/R AML.
• Summary of ongoing trials investigating gilteritinib in combination regimens.

Main Results:

• The ADMIRAL study demonstrated superior overall survival and higher response rates with gilteritinib compared to salvage chemotherapy in R/R AML.
• Gilteritinib, a dual FLT3/AXL inhibitor, offers targeted therapy for patients with specific FLT3 mutations.
• Ongoing trials are exploring novel combinations involving gilteritinib to further enhance treatment outcomes.

Conclusions:

• Gilteritinib represents a significant advancement in treating R/R FLT3-mutated AML.
• The ADMIRAL study findings suggest a potential paradigm shift towards gilteritinib as the standard therapy for this patient population.
• Further research into gilteritinib combinations aims to optimize its role in AML management.